Search

Author/Creator Multani, P.S.

1. 29LBA Entrectinib (RXDX-101), an oral pan-Trk, ROS1, and ALK inhibitor in patients with advanced solid tumors harboring gene rearrangements. (September 2015)

Authors:
Siena, S.; Drilon, A.E.; Sai-Hong Ou, I.; Farago, A.F.; Patel, M.; Bauer, T.M.; Hong, D.; Liu, S.V.; Lee, J.; Patel, R.; Schechet, L.; Luo, D.; Chow Maneval, E.; Multani, P.S.; De Braud, F.G.
Journal:
European journal of cancer
Issue:
Volume 51:(2015)Supplement 3
Page Start:
S724
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. A phase 1/1b study of RXDX-105, an oral RET and BRAF inhibitor, in patients with advanced solid tumors. (December 2016)

Authors:
Drilon, A.; Marwan, F.; Fu, S.; Patel, M.R.; Olszanski, A.J.; Lockhart, A.C.; Liu, S.V.; Bazhenova, L.; Seery, T.; Nikolinakos, P.; Patel, R.; Oliver, J.W.; Multani, P.S.; Wang, D.
Journal:
European journal of cancer
Issue:
Volume 69(2016)supplement 1
Page Start:
S143
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search